Synergistic Up-regulation of the Myeloid-specific Promoter for the Macrophage Colony-stimulating Factor Receptor by AML1 and the T(8;21) Fusion Protein May Contribute to Leukemogenesis

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1996 Oct 15

PMID 8876234

Citations 30

Authors

K L Rhoades

C J Hetherington

J D Rowley

S W Hiebert

G Nucifora

D G Tenen

D E Zhang

Affiliations

Soon will be listed here.

Abstract

AML1 is involved in the (8;21) translocation, associated with acute myelogenous leukemia (AML)-type M2, which results in the production of the AML1-ETO fusion protein: the amino-terminal 177 amino acids of AML1 and the carboxyl-terminal 575 amino acids of ETO. The mechanism by which AML1-ETO accomplishes leukemic transformation is unknown; however, AML1-ETO interferes with AML1 transactivation of such AML1 targets as the T-cell receptor beta enhancer and the granulocyte-macrophage colony-stimulating factor promoter. Herein, we explored the effect of AML1-ETO on regulation of a myeloid-specific AML1 target, the macrophage colony-stimulating factor (M-CSF) receptor promoter. We found that AML1-ETO and AML1 work synergistically to transactivate the M-CSF receptor promoter, thus exhibiting a different activity than previously described. Truncation mutants within the ETO portion of AML1-ETO revealed the region of ETO necessary for the cooperativity between AML1 and AML1-ETO lies between amino acids 347 and 540. Endogenous M-CSF receptor expression was examined in Kasumi-1 cells, derived from a patient with AML-M2 t(8;21) and the promonocytic cell line U937. Kasumi-1 cells exhibited a significantly higher level of M-CSF receptor expression than U937 cells. Bone marrow from patients with AML-M2 t(8;21) also exhibited a higher level of expression of M-CSF receptor compared with normal controls. The upregulation of M-CSF receptor expression by AML1-ETO may contribute to the development of a leukemic state in these patients.

Citing Articles

RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.

Zhen T, Cao Y, Ren G, Zhao L, Hyde R, Lopez G Blood. 2020; 136(21):2373-2385.

PMID: 32929473 PMC: 7685208. DOI: 10.1182/blood.2020007747.

deficiency delays leukemogenesis in mice induced by .

Zhen T, Kwon E, Zhao L, Hsu J, Hyde R, Lu Y Blood. 2017; 130(22):2431-2442.

PMID: 29018080 PMC: 5709785. DOI: 10.1182/blood-2017-04-780106.

New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Li J, Guo C, Steinauer N, Zhang J Front Biol (Beijing). 2017; 11(4):285-304.

PMID: 28261265 PMC: 5336278. DOI: 10.1007/s11515-016-1415-1.

Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.

Hyde R, Zhao L, Alemu L, Liu P Leukemia. 2015; 29(8):1771-8.

PMID: 25742748 PMC: 4526349. DOI: 10.1038/leu.2015.58.

Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta.

Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W J Virol. 2012; 87(3):1906-11.

PMID: 23175372 PMC: 3554157. DOI: 10.1128/JVI.02199-12.

References

Voso M, Burn T, Wulf G, Lim B, Leone G, Tenen D . Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. Proc Natl Acad Sci U S A. 1994; 91(17):7932-6. PMC: 44518. DOI: 10.1073/pnas.91.17.7932. View

Pharr P, Ogawa M, Hofbauer A, Longmore G . Expression of an activated erythropoietin or a colony-stimulating factor 1 receptor by pluripotent progenitors enhances colony formation but does not induce differentiation. Proc Natl Acad Sci U S A. 1994; 91(16):7482-6. PMC: 44425. DOI: 10.1073/pnas.91.16.7482. View

Zhang D, Fujioka K, Hetherington C, Shapiro L, Chen H, Look A . Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol. 1994; 14(12):8085-95. PMC: 359347. DOI: 10.1128/mcb.14.12.8085-8095.1994. View

Nucifora G, Rowley J . The AML1 and ETO genes in acute myeloid leukemia with a t(8;21). Leuk Lymphoma. 1994; 14(5-6):353-62. DOI: 10.3109/10428199409049690. View

Levanon D, NEGREANU V, Bernstein Y, Bar-Am I, Avivi L, Groner Y . AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics. 1994; 23(2):425-32. DOI: 10.1006/geno.1994.1519. View

Meyers S, Lenny N, Hiebert S . The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol. 1995; 15(4):1974-82. PMC: 230424. DOI: 10.1128/MCB.15.4.1974. View

Borycki A, Foucrier J, Saffar L, Leibovitch S . Repression of the CSF-1 receptor (c-fms proto-oncogene product) by antisense transfection induces G1-growth arrest in L6 alpha 1 rat myoblasts. Oncogene. 1995; 10(9):1799-811. View

Golub T, Barker G, Bohlander S, Hiebert S, Ward D, Morgan E . Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 1995; 92(11):4917-21. PMC: 41818. DOI: 10.1073/pnas.92.11.4917. View

Takahashi A, Satake M, Yamaguchi-Iwai Y, Bae S, Lu J, Maruyama M . Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood. 1995; 86(2):607-16. View

10.

Sun W, Graves B, Speck N . Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. J Virol. 1995; 69(8):4941-9. PMC: 189309. DOI: 10.1128/JVI.69.8.4941-4949.1995. View

11.

Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T . Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res. 1995; 23(14):2762-9. PMC: 307102. DOI: 10.1093/nar/23.14.2762. View

12.

Bourette R, Myles G, Carlberg K, Chen A, Rohrschneider L . Uncoupling of the proliferation and differentiation signals mediated by the murine macrophage colony-stimulating factor receptor expressed in myeloid FDC-P1 cells. Cell Growth Differ. 1995; 6(6):631-45. View

13.

Era T, Asou N, Yamaguchi K, Yamasaki H, Kamada N, Nishikawa S . Expression of AML1 and ETO Transcripts in hematopoietic cells. Leukemia. 1995; 9 Suppl 1:S26-8. View

14.

Lenny N, Meyers S, Hiebert S . Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene. 1995; 11(9):1761-9. View

15.

Feinstein P, Kornfeld K, Hogness D, Mann R . Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue. Genetics. 1995; 140(2):573-86. PMC: 1206636. DOI: 10.1093/genetics/140.2.573. View

16.

Frank R, Zhang J, Uchida H, Meyers S, Hiebert S, Nimer S . The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene. 1995; 11(12):2667-74. View

17.

Okuda T, van Deursen J, Hiebert S, Grosveld G, Downing J . AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996; 84(2):321-30. DOI: 10.1016/s0092-8674(00)80986-1. View

18.

Zhang D, Hetherington C, Meyers S, Rhoades K, Larson C, Chen H . CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996; 16(3):1231-40. PMC: 231105. DOI: 10.1128/MCB.16.3.1231. View

19.

Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe A, Speck N . Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996; 93(8):3444-9. PMC: 39628. DOI: 10.1073/pnas.93.8.3444. View

20.

Hiebert S, Sun W, Davis J, Golub T, Shurtleff S, Buijs A . The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol. 1996; 16(4):1349-55. PMC: 231119. DOI: 10.1128/MCB.16.4.1349. View